Rousculp, M.D.; Hollis, K.; Ziemiecki, R.; Odom, D.; Marchese, A.M.; Montazeri, M.; Odak, S.; Jackson, L.; Beyhaghi, H.; Toback, S.
Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines. Vaccines 2024, 12, 802.
https://doi.org/10.3390/vaccines12070802
AMA Style
Rousculp MD, Hollis K, Ziemiecki R, Odom D, Marchese AM, Montazeri M, Odak S, Jackson L, Beyhaghi H, Toback S.
Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines. Vaccines. 2024; 12(7):802.
https://doi.org/10.3390/vaccines12070802
Chicago/Turabian Style
Rousculp, Matthew D., Kelly Hollis, Ryan Ziemiecki, Dawn Odom, Anthony M. Marchese, Mitra Montazeri, Shardul Odak, Laurin Jackson, Hadi Beyhaghi, and Seth Toback.
2024. "Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines" Vaccines 12, no. 7: 802.
https://doi.org/10.3390/vaccines12070802
APA Style
Rousculp, M. D., Hollis, K., Ziemiecki, R., Odom, D., Marchese, A. M., Montazeri, M., Odak, S., Jackson, L., Beyhaghi, H., & Toback, S.
(2024). Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines. Vaccines, 12(7), 802.
https://doi.org/10.3390/vaccines12070802
